These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15359828)

  • 41. Hepatitis C virus (HCV) reactivation caused by steroid therapy for dermatomyositis.
    Mori N; Imamura M; Takaki S; Araki T; Hayes NC; Aisaka Y; Chayama K
    Intern Med; 2014; 53(23):2689-93. PubMed ID: 25447651
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Detection of HCV antibody-negative donations: Saudi experience with nucleic acid testing.
    Hajeer AH; Al Gharawi K; Al Rayes W; Qasem L; Merenkov Z; Al Balwi M
    Br J Biomed Sci; 2008; 65(2):103-4. PubMed ID: 19055115
    [No Abstract]   [Full Text] [Related]  

  • 43. Acute HCV infection detected in a blood donor by NAT.
    Coste J; Levayer T; Izopet J; Laperche S; Parneix P; Rech H; Payen JL; Schved JF
    Transfusion; 2003 Jan; 43(1):116-8. PubMed ID: 12519440
    [No Abstract]   [Full Text] [Related]  

  • 44. Detection of hepatitis C virus antibody and RNA in hemostatic gauze used for dentistry.
    Hasegawa H; Yamada T; Esumi M
    Infect Control Hosp Epidemiol; 2003 Feb; 24(2):137-9. PubMed ID: 12602697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Full or partial seroreversion in patients infected by hepatitis C virus.
    Lefrère JJ; Guiramand S; Lefrère F; Mariotti M; Aumont P; Lerable J; Petit JC; Girot R; Morand-Joubert L
    J Infect Dis; 1997 Feb; 175(2):316-22. PubMed ID: 9203652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinico-pathological study of so-called asymptomatic HCV carrier].
    Sugiyama T; Shimizu M; Kojima M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):557-61. PubMed ID: 7563824
    [No Abstract]   [Full Text] [Related]  

  • 47. [Advances in studies of HCV nucleic acid testing for clinical diagnosis].
    Xu B; He XX; Ren YN; Wang J; Xing WW
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jan; 42(1):153-159. PubMed ID: 33503713
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HCV and tumors of the immune system.
    Paydas S
    Leuk Res; 2002 Dec; 26(12):1141. PubMed ID: 12443891
    [No Abstract]   [Full Text] [Related]  

  • 49. Combination of serological markers to predict the presence or absence of viremia in HCV-seropositive blood donors.
    Gérard C; Vaira D; Maggipinto G; Troonen H; Margraff U; Siquet J; Sondag D
    Vox Sang; 1996; 71(1):58-60. PubMed ID: 8837360
    [No Abstract]   [Full Text] [Related]  

  • 50. Indirect tests to detect the non-A, non-B hepatitis carrier state.
    Alter HJ; Holland PV
    Ann Intern Med; 1984 Dec; 101(6):859-61. PubMed ID: 6437311
    [No Abstract]   [Full Text] [Related]  

  • 51. Usefulness of IgM anti-HCV in differential diagnosis between recurrent hepatitis C and acute rejection in liver transplant patients.
    Ciccorossi P; Filipponi F; Oliveri F; Romagnoli J; Urbani L; Marciano E; Catalano G; Bonino F; Mosca F; Brunetto MR
    Transplant Proc; 2001; 33(7-8):3641-2. PubMed ID: 11750546
    [No Abstract]   [Full Text] [Related]  

  • 52. [Interpretation and inform guide on the anti HCV antibody].
    Hernández-Calleros J
    Rev Invest Clin; 2012; 64(6 Pt 2):594-5. PubMed ID: 23593775
    [No Abstract]   [Full Text] [Related]  

  • 53. Anti-HCV signal-to-cutoff ratio in predicting hepatitis C viremia.
    Kim HS
    Korean J Intern Med; 2009 Dec; 24(4):299-301. PubMed ID: 19949726
    [No Abstract]   [Full Text] [Related]  

  • 54. Diagnostics: a testing journey.
    DeWeerdt S
    Nature; 2011 Jun; 474(7350):S20-1. PubMed ID: 21666732
    [No Abstract]   [Full Text] [Related]  

  • 55. Follow-up testing for hepatitis C virus infection: an analysis of Massachusetts surveillance data, 2007-2010.
    Barton K; Church D; Onofrey S; Cocoros N; DeMaria A
    Public Health Rep; 2014; 129(5):403-7. PubMed ID: 25177051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of electronic health record clinical decision support tool for HCV birth cohort screening.
    Fitch DN; Dharod A; Campos CL; Núñez M
    J Viral Hepat; 2017 Nov; 24(11):1076. PubMed ID: 28544048
    [No Abstract]   [Full Text] [Related]  

  • 57. HCV and PCR negativity.
    Irving WL; Day S; Eglin RP; Bennett DP; Jones DA; Nuttall P; James V
    Lancet; 1992 Jun; 339(8806):1425. PubMed ID: 1350841
    [No Abstract]   [Full Text] [Related]  

  • 58. [Value of techniques of molecular biology in the management of hepatitis C virus infections].
    Loiseau P
    Presse Med; 1997 Oct; 26(29):1393-8. PubMed ID: 9404350
    [No Abstract]   [Full Text] [Related]  

  • 59. [Current status of nucleic acid testing for hepatitis C].
    Wang Y; Mao YR
    Zhonghua Gan Zang Bing Za Zhi; 2021 Aug; 29(8):803-806. PubMed ID: 34517465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology.
    Gorodin S; Unal S; Wang Y; Mikhaylov MI; Bigbulatova L; Jehuda-Cohen T
    ScientificWorldJournal; 2013; 2013():389780. PubMed ID: 23476130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.